| Paper 1 | |
|---|---|
| Patient Name | Fawzeya Abdellatif Mohamed |
| Age | 76 |
| Clinical evaluation | |
| Consultation date | 01/18/2025 |
| Previous assessment for TAVI | yes |
| History and risk factors | |
| Prior CABG | no |
| Prior aortic valve procedure | no |
| Prior other valve procedure | no |
| Number of previous cardiac surgery | none |
| Prior arrhythmia | no |
| Permanent peacemaker | no |
| Other history | |
| Previous CVA or TIA | no |
| Extracardiac arteriopathy | no |
| Hypertension | yes |
| Diabetes melitus | no |
| Renal insufficiency requiring dialysis | no |
| Renal insufficiency requiring renal transplant | no |
| Chronic lung disease | no |
| Malignancy (prior or current) | no |
| Paper 2 | |
| Clinical evaluation continued | |
| Syncope | no |
| CCS | no |
| NYHA | II |
| Clinical data | |
| Height (cm) | 166 |
| Weight (kg) | 79 |
| Hemoglobin (g/dl) | 11.3 |
| Creatinine (mg/dl) | 1.2 |
| Pre-operative special investigations | |
| ECG | |
| Rhythm | regular |
| PR Interval (ms) | 130 |
| QRS Duration (ms) | 100 |
| ECHO (TTE or TOE) | |
| Mean gradient across aortic valve (mm Hg) | 45 |
| Aortic valve area (cm2) | 0.9 |
| Ejection fraction (%) | 67 |
| Associated valvular lesions | |
| Aortic insufficiency | none |
| Mitral insufficiency | mild |
| Mitral stenosis | none |
| Tricuspid insufficiency | none |
| Tricuspid stenosis | none |
| Pulmonary insufficiency | none |
| Pulmonary stenosis | none |
| Paper 3 | |
| TAVI evaluation | |
| Risk profile | |
| Predicted operative risk | low |
| STS score (%) | 3.2 |
| Euroscore II (%) | 2.4 |
| Contra-indication to surgery | no |
| Reason for contra-indication to surgery | |
| Frailty | no |
| Porcelain aorta | no |
| Patent LIMA graft | no |
| Hostile thorax | no |
| Further investigations | |
| Lung function tests | no |
| Angiogram | no |
| PCI or revascularization indicated | no |
| CT coronary angiogram | no |
| Pre TAVI CT Assessment | |
| Aortic Annulus | |
| Perimeter (mm) | 80.7 |
| Perimeter derived (mm) | 25 |
| AREA (mm2) | 506.2 |
| Area derived (mm) | 25.3 |
| LVOT | |
| Perimeter (mm) | 77 |
| Perimeter derived (mm) | 24.3 |
| AREA (mm2) | 471.7 |
| Area derived (mm) | 24.2 |
| Sinus of Valsalva | |
| Left | 33 |
| Right | 33 |
| Non | 33.8 |
| Measurements | |
| Aortic Annulus | |
| LVOT | |
| STJ angle | |
| Min | 29.3 |
| Max | 29.9 |
| Average | 30.2 |
| LCA Height | 14 |
| RCA Height | 17 |
| Aortic Valve Calcification | moderate |
| Aortic Root Angulation | 58 |
| Paper 4 | |
| TAVI procedure | |
| Type of anesthesia | local |
| TOE used intra-operatively | no |
| Valve in valve procedure | no |
| Procedural success | yes |
| Procedural complications (VARC < 72 hours) | |
| Intra-procedural mortality | no |
| Consequent mortality < 72 hr post-procedure | no |
| Myocardial infarction | no |
| Stroke or TIA | no |
| New PML | no |
| Bleeding complications | no |
| Vascular complication | no |
| Valve dysfunction | no |
| Other thrombotic or embolic complications | no |
| Cardiopulmonary bypass required | no |
| Other procedural complications | yes |
| Conversion to open heart surgery | no |
| Device information | |
| Number of valves implanted | 1 |
| Valve 1 | |
| Type implanted | Medtronic |
| Medtronic data | |
| Model implanted | Evolut R |
| Size implanted | 29 |
| Boston data | |
| Hospital stay | |
| Paper 5 | |
| Follow up information | |
| General follow up | |
| Stroke / TIA since TAVI | no |
| PPM since TAVI | yes |
| PPM – timeframe | post-procedural |
| Reason of PPM | CHB |
| Hospital admission | yes |
| Number of admission | 3 |
| Follow up 30 days | |
| Stroke / TIA since TAVI | no |
| PPM since TAVI | yes |